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Abstract
Background: The American Thyroid Association (ATA) and more recently the European Thyroid Association (ETA)
Guidelines on diagnosis and treatment of medullary thyroid carcinoma (MTC) have provided an excellent tool
which was formerly lacking in the field of management of MTC. However, some relevant clinical questions, as the
use of somatostatin analogues in the treatment of MTC and the management of pregnant patients with MTC,
which were recommended in the guidelines, have been lately extensively revised. Moreover the current issue
whether GLP-1 (a glucagon-like peptide-1) analogue is associated with MTC has only superficially been analyzed.
Methods: Publications have been retrieved in MEDLINE at Pubmed (there is no fix date retrospectively) up to
October 2012 using the terms “medullary thyroid carcinoma”, “somatostatin”, “pregnancy” and “incretins”. The
recommendations made by ATA and ETA were considered.
Conclusions: There are no data supporting the application of somatostatin analogues in the treatment of MTC,
while thyroid cancer during or after pregnancy has no impact on the prognosis of disease or on the outcome of
pregnancy. However, women with MEN 2 should be carefully controlled before any planned or during any
unplanned pregnancy. In contrast to animal studies, there are no consistent human data supporting a stimulatory
effect of GLP-1 receptor activation by liraglutide, an incretin mimetic, on calcitonin levels, though establishment of
a registry and further studies are required to exclude any association between GLP-1 analogue and MTC.
Background
MTC, which accounts for 5-8% of all thyroid cancers, is
mainly sporadic in nature, while a hereditary pattern
(multiple endocrine neoplasia type 2 (MEN 2), trans-
mitted as an autosomal-dominant trait due to germline
mutations of the RET proto-oncogene, accounts for
about 29% of cases [1].
In 2009, at the ETA annual meeting in Lisbon, the Eur-
opean Thyroid Association-Cancer Research Network
(ETA-CRN) extensively commented on the American
Thyroid Association Guidelines regarding the diagnosis
and treatment of medullary thyroid cancer (MTC) pub-
lished earlier that year [2]. These, in conjunction with the
2011 European Thyroid Association (ETA) Guidelines [3],
succeeded in compensating for the previous lack of con-
sensus on the management of this rare disease and now
present a platform for optimal diagnostic and therapeutic
approach to MTC, one which moreover demands multi-
disciplinary engagement. Some of the above mentioned
comments, updated by references to current publications
and expanded by several emerging findings, are high-
lighted in the present article which seeks to offer a broader
perspective concerning certain clinical queries and the
recommendations made.
Clinical questions
An oft-posed query: might somatostatin analogues be
applicable as antitumor agents in MTC?
MTC is derived from the neural crest and exhibits a
widely variable expression of somatostatin receptors
which have been used in the detection of disease. Initially
octreotide and recently 68Ga DOTA-peptides PET have
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been successfully employed for the detection of MTC
neuroendocrine tumors [4]. More recent developments
have provided encouraging results in imaging modalities
of MTC, such as PET/CT with beta-emitter labeled
DOTANOC, characterized by great affinity to the soma-
tostatin receptors [5]. However, (18)F-DOPA PET/CT
seems to be the most valuable imaging method in detect-
ing recurrent MTC [6]. The optimal treatment of MTC
is total thyroidectomy and removal of any metastatic tis-
sue from the cervical region. Thus, any alternative treat-
ment should be evaluated on an individual basis.
There are no randomized control studies but only case
series or unsystematically conducted studies which were
not able to demonstrate any consistent antitumor soma-
tostatin effect. All studies (Table 1), which in total
included 55 patients, showed subjective and biological par-
tial remission in one third and in one fourth of the MTC
patients, respectively, but no improvement in the natural
course of the tumor [7]. Somatostatin analogues, i.e.
octreotide or lanreotide, were administered at a dose of
200-1500 micrograms. Despite an initial decrease of calci-
tonin (Ct) and/of carcinoembryonic antigen (CEA) levels
of up to 68% of the basal levels, there was a rebound
within a few weeks to 84% and 105%, respectively, of the
pretreatment values, thus indicating tachyphylaxis [7,8].
However, in another study a continuous effect on Ct was
observed in two patients with MEN IIa treated with
octreotide at a dose 1.5-2 mg/day [9]. More evident was
an improvement in clinical symptoms as diarrhea, malaise
and weight loss in all the patients [9]. Nevertheless, the
results are notably heterogeneous, such as in a study
including 18 patients where a greater than 20% decrease
of Ct was apparently dependent on the dose of octreotide
and the extent of disease (10). In contrast, different formu-
lations of octreotide and lanreotide did not modify Ct and
CEA levels in five patients with recurrent MTC treated
over a period of 12 weeks [11]. In cases of advanced MTC
with ectopic corticotropin-releasing hormone (CRH) and
adrenocorticotropic hormone (ACTH) production leading
to Cushing syndrome, the use of somatostatin analogues,
especially when combined with interferon-alpha, improved
diarrhea only transitorily in a few patients [12].
In summary, somatostatin analogues are ineffective in
controlling tumor growth and are not recommended by
ATA and ETA Guidelines as antitumor agents in MTC.
Basing their assessments on the currently available
evidence, both the ATA and ETA Guidelines have
recommended against the use of somatostatin analogues
in MTC: Grade F (Rec. 84) [2] and Grade 2 and Quality
of evidence + [3].
Does medullary thyroid cancer compromise pregnancy?
There are only isolated healthcare reports of management
of thyroid cancer (TC) discovered during or after preg-
nancy and TC does not appear to have a significant impact
on the prognosis of the disease. Nor do Ct levels compro-
mise pregnancy. Increase of Ct levels without localization
of the disease should not constitute an absolute contrain-
dication of pregnancy. However, in the event that multiple
endocrine neoplasia 2A (MEN 2A), which is characterized
by MTC, adrenal pheochromocytoma and hyperparathyr-
oidism due to specific RET proto-oncogene mutations,
remains unrecognized during pregnancy, then both
woman and progeny are at risk of a crisis and of RET
mutation transmission, respectively [13].
A case of bilateral pheochromocytoma in a term-preg-
nant patient with a previous history of MTC was described
[14]. The genetic study revealed a heterozygous mutation,
c.1900T>C, in the RET proto-oncogene that confirmed
the diagnosis of multiple endocrine neoplasia type 2A
(MEN2A). Unfortunately, the tumors remained unrecog-
nized and caused a crisis with fatal outcome for the
mother during the postpartum period. This instance,
though rare, nevertheless underlines the necessity of con-
trolling pregnant patients with a history of MTC, since
early detection in such cases is capable of saving the
mother and the fetus.
The Guidelines recommend screening for pheochro-
mocytoma in women with RET mutation associated
with MEN 2 before a planned pregnancy or at the
beginning of an unplanned pregnancy: Grade B (Recom-
mendation 25) [2].
Do glucagon-like peptide-1 analogues increase the
incidence of MTC?
Studies in rodents showed that the antidiabetic agent lir-
aglutide, a glucagon-like peptide-1 (GLP-1) receptor ago-
nist, increased risk of thyroid C-cell focal hyperplasia, a
state which in rodents is considered as a preneoplastic
lesion resulting in MTC, and C-cell tumors [15]. In
Table 1 Evaluation of somatostatin analogues in advanced medullary thyroid cancer.
Reference Study Treatment / Duration No. of patients Outcome
Vainas I et al. 2004 OS Octreotide-(LAR)/ 21 months 22 No improvement of the natural course
Diez IJ, Iglesias P 2002 OS Octreotide / Lanreotide / 12 weeks 5 No effect
Frank-Raue K et al. 1993 OS Octreotide 7 No effect No beneficial effect on diarrhea
Mahler C et al. 1990 CR Octreotide / 17 months 1 2 Tachyphylaxis
Modigliani E et al. 1989 OS Octreotide / 37 days 18 Improvement of diarrhea in 2/9
OS: observational study, CR: control study
Duntas Thyroid Research 2013, 6(Suppl 1):S6
http://www.thyroidresearchjournal.com/content/6/S1/S6
Page 2 of 3
humans, increases of calcitonin in patients injecting the
incretin mimetic liraglutide, albeit falling within the nor-
mal range, were observed. Despite the acknowledged lim-
itations to extrapolating findings from animal studies to
humans, the results in rodents may possibly indicate a
low risk for humans (14). Recently, a study was designed
to determine whether GLP-1 receptor activation by lira-
glutide over a period of two years has an impact on Ct
levels in type 2 diabetes mellitus and nondiabetes obese
controls [16]. There was no consistent dose or time-
dependent relationship between treatment groups, this
suggesting that GLP-1 receptor activation has no effect
on c-cell activity. However, as has been stated by the
FDA, a cancer registry to monitor the annual incidence
of MTC over the next 15 years is required in order to
clarify any possible association between liraglutide and
MTC.
List of abbreviations used
ACTH: adrenocorticotropic hormone; CEA: carcinoembryonic antigen; CRH:
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medullary thyroid carcinoma.
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